RA
MXCT icon

Royce & Associates’s MaxCyte MXCT Stock Holding History

Royce & Associates’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-657,080
Closed -$1.43M – 814
2025
Q2 		$1.43M Sell
657,080
-383,793
-37% -$929K 0.01% 640
2025
Q1 		$2.84M Buy
1,040,873
+241,000
+30% +$950K 0.03% 533
2024
Q4 		$3.33M Buy
799,873
+475,949
+147% +$1.8M 0.03% 552
2024
Q3 		$1.26M Buy
323,924
+121,272
+60% +$511K 0.01% 697
2024
Q2 		$794K Buy
202,652
+121,224
+149% +$521K 0.01% 746
2024
Q1 		$341K Sell
81,428
-245,910
-75% -$1.15M ﹤0.01% 812
2023
Q4 		$1.54M Sell
327,338
-95,222
-23% -$371K 0.01% 685
2023
Q3 		$1.32M Buy
422,560
+23,780
+6% +$95.6K 0.01% 702
2023
Q2 		$1.83M Buy
398,780
+90,855
+30% +$418K 0.02% 674
2023
Q1 		$1.52M Buy
307,925
+37,800
+14% +$186K 0.02% 711
2022
Q4 		$1.47M Buy
270,125
+48,800
+22% +$299K 0.02% 696
2022
Q3 		$1.44M Buy
221,325
+108,325
+96% +$604K 0.02% 675
2022
Q2 		$534K Sell
113,000
-1,131,272
-91% -$5.57M 0.01% 828
2022
Q1 		$8.7M Sell
1,244,272
-59,049
-5% -$403K 0.07% 407
2021
Q4 		$13.3M Sell
1,303,321
-109,243
-8% -$1.17M 0.1% 317
2021
Q3 		$17.2M Buy
+1,412,564
New +$21.3M 0.13% 243

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates's MXCT Position: Q3 2025 in Review

Royce & Associates sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 657,080 shares — an estimated $1.43M sold.

Royce & Associates first reported a position in MXCT in Q3 2021 and held it in 16 quarters. The position peaked at $17.2M in Q3 2021. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • Royce & Associates reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • Royce & Associates sold 657,080 MaxCyte shares in Q3 2025, an estimated $1.43M.
  • Royce & Associates first reported a position in MaxCyte in Q3 2021 and held it in 16 quarters.
  • Royce & Associates's MaxCyte position peaked at $17.2M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on Royce & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.